Regeneron Pharmaceuticals (REGN) investor relations material

Strategic agreements and investments

• Secured relief from government pricing mandates and tariffs through January 2029 for wholly owned U.S. products, excluding certain alliance products.

• Committed to approximately $9 billion in capital investment in U.S. R&D and manufacturing through 2030–2031, as part of a broader $27 billion plan.

• Two-thirds of the investment will be directed toward U.S. R&D and manufacturing expenses, supporting economic objectives.

Dupixent performance and market evolution

• Dupixent serves 1.4 million patients globally, with nine U.S. indications and a $20 billion annual run rate.

• Leads in new-to-brand and total prescriptions across all indications, including atopic dermatitis, asthma, and eosinophilic esophagitis.

• Recognized as the gold standard in atopic dermatitis, with strong uptake in pediatric populations.

• COPD launch is progressing well, with patients experiencing reduced reliance on oxygen therapy and improved lung function.

• Next-generation Dupixent candidates aim to extend dosing intervals and address convenience, with clinical entry expected by year-end or early 2027.

Competitive landscape and future pipeline

• Market penetration for atopic dermatitis remains in the high teens, with new entrants helping to expand the overall market.

• Differentiation in efficacy is expected to remain challenging for competitors, as Dupixent targets the top of the biologic cascade.

• M&A opportunities are actively considered to complement the existing portfolio.